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Abstract
Background: Platelets contact each other at the site of vascular injury to stop bleeding. One negative regulator of platelet
aggregation is Disabled-2 (Dab2), which is released to the extracellular surface upon platelet activation. Dab2 inhibits
platelet aggregation through its phosphotyrosine-binding (PTB) domain by competing with fibrinogen for aIIbb3 integrin
receptor binding by an unknown mechanism.
Methodology/Principal Findings: Using protein-lipid overlay and liposome-binding assays, we identified that the N-
terminal region of Dab2, including its PTB domain (N-PTB), specifically interacts with sulfatides. Moreover, we determined
that such interaction is mediated by two conserved basic motifs with a dissociation constant (Kd) of 0.6 mM as estimated by
surface plasmon resonance (SPR) analysis. In addition, liposome-binding assays combined with mass spectroscopy studies
revealed that thrombin, a strong platelet agonist, cleaved N-PTB at a site located between the basic motifs, a region that
becomes protected from thrombin cleavage when bound to sulfatides. Sulfatides on the platelet surface interact with
coagulation proteins, playing a major role in haemostasis. Our results show that sulfatides recruit N-PTB to the platelet
surface, sequestering it from integrin receptor binding during platelet activation. This is a transient recruitment that follows
N-PTB internalization by an actin-dependent process.
Conclusions/Significance: Our experimental data support a model where two pools of Dab2 co-exist at the platelet surface,
in both sulfatide- and integrin receptor-bound states, and their balance controls the extent of the clotting response.
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Introduction
Platelets are anucleate cell fragments that contact each other to
form a plug at the site of vascular injury. Platelets contain both a-
and d-granules that contribute to their adhesion, activation, and
aggregation [1]. Granules contain a variety of proteins including
adhesive and plasma proteins, coagulation and anti-coagulation
factors, and protease inhibitors [2]. Platelet adhesion to a
prothrombotic surface is mediated by the formation of the
glycoprotein Ib-IX-V and von Willebrand factor (vWF) complex,
which is followed by the release of granules and the activation of
members of the integrin family of receptors. Activated platelets
accelerate the coagulation process by providing the membrane
surface necessary for the generation of the active form of
thrombin, which acts as a potent platelet agonist (for review, see
[3]). Thus, vWF initiates the formation of stable aggregates under
high shear flow conditions. Other complexes, such as P-selectin-
sulfatides and aIIbb3 integrin-fibrinogen, also stabilize platelet
aggregates. Thrombin cleaves fibrinogen to fibrin, which crosslinks
platelets to form the haemostatic plug.
Mammals present two Dab orthologs, Dab1 and Dab2, which
share an N-terminal PTB domain and a C-terminal proline-rich
SH3 domain, indicating that they function as adaptor proteins [4].
Dab1 is almost exclusively expressed in the brain [5], whereas
Dab2 expression is widely distributed [6]. Dab2 has been
implicated in growth factor signaling [7], endocytosis [8],
inhibition of platelet aggregation [9], and is known to interfere
with the Wnt signaling pathway [10]. Expression of Dab2 is
frequently lost in 85–90% of breast and ovarian carcinomas and
homozygous deletions of its gene have been identified in a small
percentage of tumors [6,11]. Downregulation of Dab2 has been
identified in a disparity of cancers including esophageal [12] and
prostate carcinomas [13] and found associated to early stage
events [14]. These observations led to the hypothesis that Dab2 is
a tumor suppressor.
The PTB domain is evolutionarily conserved and often found in
proteins containing other protein-protein interaction domains.
This module was initially recognized to bind tyrosine-phosphor-
ylated (pTyr) NPXY motifs [15]. However, the Dab2 PTB domain
interacts with several non-phosphorylated NPXY-containing
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protein 1 [8] and Dishevelled-3 [10]. The Dab2 PTB domain
plays a key role in the LDL receptor internalization as Dab2
co-localizes with clathrin coats on the cell membrane during
endocytosis [8,16]. In Dab1, the PTB domain preferentially binds
to phosphatidylinositol 4,5-biphosphate (PtdIns(4,5)P2) [16], an
interaction that has been proposed to target Dab1 to membranes
[17]. In Dab2, the PTB domain mediates binding of the protein to
both the lipoprotein receptor and PtdIns(4,5)P2 during endocytosis
[16]. In addition, the PTB domain mediates binding of Dab2 to
the aIIbb3 integrin receptor, thus, exerting its negative role in
platelet aggregation [9] by an unknown mechanism.
Sulfatides, the sulfuric ester of galactosylceramides at the C3 of
the galactose residue, are present at the cell surface and are thought
to influence the activity of integral membrane proteins [18].
Sulfatides are known to participate in cell adhesion, differentiation
and signal transduction [19]. This sphingolipid, which increases its
levels upon platelet activation [20], has been shown to bind
coagulation proteins including vWF [21], P-selectin [22], and
thrombospondin [23], thus, playing a key role in haemostasis. Here,
we have specifically investigated the mechanism by which Dab2
regulates platelet function. We found that the N-terminal region of
Dab2 specifically binds sulfatides through two conserved polybasic
motifs, and this association partitions the protein into two pools at
the platelet surface, the sulfatide- and integrin receptor-bound
states, thus, modulating the extent of platelet activation.
Methods
DNA Cloning, Plasmids, and Protein Expression and
Purification
The Dab2 N-PTB (residues 1-241) cDNA was cloned into
pGEX6P1 (GE Healthcare). Site-directed mutagenesis of Dab2 N-
PTB was performed using Quick Change (Stratagene). Proteins
were expressed in E.coli Rosetta and purified on glutathione beads
as described [24]. Purity of all proteins was over 95% as judged by
SDS-PAGE.
Protein-Lipid Overlay Assay
Membrane strips (Echelon Research Laboratories) spotted with
100 pmoles of sphingolipids were incubated with 0.1 mg/ml of N-
PTB or its mutants in 20 mM Tris-HCl (pH 8.0), 150 mM NaCl,
0.1% Tween-20, and 3% fatty acid-free BSA overnight at 4uC.
Following four washes with the same buffer, bound proteins were
probed with rabbit anti-GST antibody (Santa Cruz Biotech) and
donkey anti rabbit-horse radish peroxidase (HRP) (GE Health-
care). Protein binding was detected using ECL reagent (Pierce).
Lipid strips were prepared by spotting 1 ml of the indicated
amount of either sulfatide or PtdIns(4,5)P2 dissolved in chlor-
oform:methanol:water (1:2:0.8 and 65:35:8, respectively) onto
Hybond-C extra membranes (GE Healthcare) and protein binding
was monitored as described above.
Liposome-Binding Assay
Stocks of brain sulfatides, phosphatidylcholine (PC), phospha-
tidylethanolamine (PE), phophatidylserine (PS) (Avanti Polar
Lipids), cholesterol (Sigma) and PtdIns(4,5)P2 (Cayman Chemicals)
were prepared in organic solvents per manufacturer instructions.
Sulfatide liposomes were prepared by weight ratio of 1:1:1:4 of
PC:PE:cholesterol:sulfatides. PtdIns(4,5)P2 liposomes were pre-
pared by percent ratio of 50:20:10:10:10 of PC:PE:PS:cholester-
ol:PtdIns(4,5)P2. Controls were prepared by adjusting the ratios
with PC. Lipid films were generated by lyophilization and
hydrated in 20 mM Tris-HCl (pH 6.8) and 100 mM NaCl to
1 mg/mL at 60uC for 1 h. Liposomes were sonicated, pelleted,
and suspended at 2.5 mg/mL in the same buffer. Ten mgo f
protein was incubated with 125 mg of total lipid for 20 min at
23uC. Liposome-bound and free-protein samples were separated
by centrifugation and analyzed by SDS-PAGE.
Surface Plasmon Resonance
SPR binding experiments were performed on a BIAcore X
instrument using L1 sensorchips coated with ,0.5 mM of mixed
sulfatides or PtdIns(4,5)P2 100 nm size-calibrated liposomes. The
Dab2 N-PTB binding experiments were performed in 10 mM
Tris-HCl (pH 7.4) and 100 mM NaCl. This buffer was used
during the equilibration, association, and dissociation phases.
Proteins were added to this buffer at the indicated concentrations.
Regeneration of the lipid bilayer after the dissociation phase was
carried out using 20 mM NaOH. The data were globally fit using
BIAevaluation 3.0.
Thrombin-Limited Proteolysis
Sulfatide and PtdIns(4,5)P2 liposomes were incubated with
10 mg of protein for 20 min at 23uC, centrifuged, and the pellets
suspended in 50 ml of 20 mM Tris-HCl (pH 6.8) and 100 mM
NaCl. Thrombin (0.05 units/mg protein) was added to both
supernatants and pellets and aliquots were taken at 0, 8, 12, 16,
and 20 h after digestion. Reactions were stopped with Laemmli
buffer and analyzed by SDS-PAGE.
Immunofluorescence Analysis
Studies on human platelets were carried out with ethical
approval from the Office of Research Compliance at Virginia
Tech, with written informed consent obtained from all donors.
Washed platelets from healthy human volunteers (6610
6 platelets)
were incubated with 1.9 mM of untagged N-PTB constructs for
5 min at 23uC in the presence of 0.25 g/L fibrinogen. Activation
was initiated by the addition of 10 mM TRAP. Reactions were
incubated at 23uC unless otherwise indicated.
Platelets were fixed with 3.7% formaldehyde in phosphate buffered
saline (PBS) for 30 min. Next, 20% goat serum was added to the fixed
platelets and 60% of the total fixed reaction was cytospun onto a
Shandon-coated cytoslide. Slides were then washed twice with PBS for
10 min. Platelets were permeabilized with 0.5% Triton X-100 in PBS
for 10 min and then blocked with 20% goat serum in PBS containing
0.1% Triton X-100 for 1 h at room temperature. Platelets were washed
three times with PBS with 0.1% Triton for 10 min and analyzed as
described [25] using anti-Dab2 (anti-p96; BD Transduction), Cy-3
conjugated goat anti-mouse antibody (Sigma), and Alexa488 conjugated
phalloidin (5 U/mL; Invitrogen). Platelets were observed on an
Olympus IX71 microscope, using a 10 0 xN A1 . 4U P I a n S A p oo b j e c t i v e
lens. Images were captured with a charge-coupled device camera
(Photometrics CoolSNAP HQ2CCD) and analyzed using SoftWorx
software (Applied Precision). Mean pixel intensity was determined for at
least 450 platelets from at least four fields. For inhibition assays, platelets
were incubated with 0.25 g/L fibrinogen with either 28 mMc h l o r -
promazine (3 min), 4 mM cytochalasin D (5 min), 1.5 mM filipin
(60 min), 5 mM MBCD (20 min) (Sigma) or vehicle. N-PTB, N-
PTB
4M,o rN - P T B
D66E (1.9 mM) was then added and the reaction
incubated for 4 min. TRAP (10 mM) was then added to initiate the
reactions and samples were processed as described above.
Platelet Adhesion Assay
Non-tissue culture plates were incubated with fibrinogen
(20 mg/mL) for 2 h at 37uC, washed with PBS and blocked with
5% fatty acid-free BSA for 24 h at 4uC. After three washes, 2610
7
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N-PTB
4M, or N-PTB
D66E (1 mM each) and TRAP (10 mM) for
20 min at 37uC. Bound platelets were quantified as described [26].
Flow Cytometry Analysis
A mixture of 50 mM of protein or peptide, 1 mg/mL final FITC-
labeled PAC-1 antibody (BD Transduction), 5 ml APC-CD42b
(BD Transduction), and 10 mM TRAP were mixed and incubated
with 1610
6 washed human platelets for 10 min at 23uC. Platelets
were fixed with 1% formalin for 15 min at 23uC. Bound PAC-1
antibody was measured using a FacsAria flow cytometer. For the
expression of the endogenous integrin receptor assay, platelets
were activated with 30 mM ADP and further incubated with
liposomes (50 mg/mL) and in the absence or presence of Dab2 N-
PTB constructs (1 mM). Platelets were processed as described
above.
Statistical Analysis
Statistics were analyzed using the Student’s t test (p-value,0.05,
statistically significant).
Results and Discussion
Identification of Sulfatide-Binding Sites in Dab2
Analysis of the amino acid sequence of the N-terminal region of
Dab2, including its PTB domain, showed the presence of
conserved positively charged residues that closely resemble two
characteristic sulfatide-binding sites, the XBBXBX and BXBXBX
motifs [27] (B, basic; X, any residue; Fig. 1A) described in other
haemostatic proteins, including laminin-1 [28] and vWF [29].
Therefore, we analyzed the N-terminal region of Dab2 (residues 1-
241; N-PTB) for binding to sulfatides in comparison with other
sphingolipids found at the plasma membrane. Our results show
that N-PTB specifically binds to sulfatides as analyzed by the
protein-lipid overlay assay (Fig. 1B and Fig. S1A). Because the
Dab2 PTB targets membranes [9], we then employed liposomes
enriched with sulfatides to further investigate the interaction. We
found that N-PTB binds to sulfatide liposomes (Fig. 1C and Fig.
S1B). Single mutations to Ala designed within the putative
sulfatide-binding sites (Lys25, Lys49, or Lys53) or a combination
of two mutations (Lys25 and Lys49) reduced but did not eliminate
sulfatide binding (Fig. 1C and Fig. S1C). However, a substitution
of four positively charged residues (Lys25, Lys49, Lys51, and
Lys53; N-PTB
4M) to Ala (Fig. 1A) completely abolished sulfatide
binding (Fig. 1C, Fig. S1A and B). Circular dichroism spectra of
N-PTB
4M and mutants exhibit similar overall secondary structure
content compared with N-PTB, indicating that mutations do not
significantly perturb the global fold of the protein (Text S1, Fig. S2
and Table S1). Thus, these results identify two positively charged
motifs in N-PTB that play a critical role in sulfatide recognition.
Sulfatide- and PtdIns(4,5)P2-Binding Sites Share Lys53 in
N-PTB
The Dab2 PTB domain is known to bind phosphoinositides
with a preference for PtdIns(4,5)P2 [16], independent of the
receptor interaction site [30]. Two basic residues (Lys53 and
Lys90) have been reported to play a critical role in PtdIns(4,5)P2
recognition [31]. Because we found that Lys53 is involved in
sulfatide binding, we then examined whether Lys90 could also be
critical for sulfatide recognition. Mutations in both Lys53 and
Lys90 to Ala (N-PTB
K53K90) reduced sulfatide binding by about 3-
fold (Fig. 1C), similarly to a sole mutation at Lys53 (Fig. S1C).
However, a single mutation at Lys90 (N-PTB
K90) resembled
sulfatide binding by N-PTB (Fig. 1C), indicating that Lys90 is not
required for sulfatide recognition. As expected, N-PTB bound to
PtdIns(4,5)P2 liposomes, whereas N-PTB
K53K90 and N-PTB
4M did
not (Fig. 1D). Unlike the Lys53 mutant, single or double mutations
in the sulfatide-binding sites in N-PTB did not significantly affect
PtdIns(4,5)P2 binding (Fig. 1D and Fig. S3). Mutations in Lys53
and Lys90 did not alter the overall secondary structure of the
protein, indicating that they specifically abolished lipid binding
(Text S1, Fig. S2 and Table S1). Although sulfatides and
PtdIns(4,5)P2 require Lys53 for N-PTB recognition, it is unlikely
that they can physiologically compete with each other for binding
to Dab2 since sulfatides are present on external membrane
surfaces [20], whereas PtdIns(4,5)P2 is found on the inner leaflet
[32]. Next, we investigated the kinetics of lipid interaction with N-
PTB by SPR. The N-PTB displayed reversible binding to either
immobilized sulfatide or PtdIns(4,5)P2 liposomes, and both fit a
two-state reaction with conformational change interaction model.
The N-PTB bound to sulfatides with an estimated Kd of 0.6 mM
(x2=2.6) (Fig. 2), a value similar to that reported for sulfatide
binding by annexin V [33]. The N-PTB bound to PtdIns(4,5)P2
with a calculated Kd of 3.6 mM( x2=5.1) (Fig. 2), which is in the
range of that reported for the Dab1 PTB domain [34].
Sulfatides Protect N-PTB from Thrombin Cleavage
Platelets not only secrete molecules that facilitate blood
coagulation but also participate in haemostasis by secreting
various anti-coagulant proteins from their a-granules, thus,
limiting the progression of blood clotting [2]. For example, during
platelet activation, Dab2 is released from a-granules to the platelet
surface and binds to the extracellular region of the aIIbb3 integrin,
where it exerts its anti-platelet aggregation activity [9]. Thrombin,
a strong platelet agonist, cleaves Dab2 in its PTB domain; thus,
Dab2 could be proteolyzed during thrombin-mediated platelet
activation [9]. Our results indicate that thrombin cleaved N-PTB,
leaving a protease-resistant product (Fig. 3A). To examine the role
of Dab2-sulfatide binding in the context of thrombin-mediated
platelet activation, N-PTB was pre-incubated with sulfatide
liposomes and protein-lipid complexes were treated with throm-
bin. Interestingly, sulfatide liposomes partially protected N-PTB
from thrombin cleavage (Fig. 3B). Mass spectrometry analyses of
trypsin-digested, thrombin-resistant polypeptides indicated that
the first sulfatide-binding site of N-PTB is located upstream of a
putative thrombin cleavage site (Lys30, Gly31) and protected from
cleavage when bound to sulfatide liposomes (Fig. 1A, 3B, and C).
Although thrombin cleavage of Dab2 might lead to the loss of
Dab2 inhibitory activity in a platelet aggregation assay [9], we
hypothesize that Dab2 binding to sulfatides at the platelet surface
could protect the protein from thrombin cleavage (our results)
while contributing to blocking sulfatides needed for pro-coagulant
interactions [20]. In contrast, PtdIns(4,5)P2 was unable to protect
N-PTB from thrombin cleavage (Fig. 3D), indicating that the
phosphoinositide does not have a direct role in Dab2 stabilization
during thrombin-mediated platelet activation.
Sulfatides Mediate Localization and Internalization of
N-PTB
The N-PTB has been shown to bind to the integrin receptor [9]
and sulfatides (this study). Thus, we hypothesize that two pools of
Dab2 co-exist at the activated platelet surface. Consequently, we
analyzed the subcellular localization of endogenous Dab2, as well
as exogenously added N-PTB and N-PTB
4M during thrombin
receptor-activating peptide (TRAP)-mediated platelet activation
(Fig. 4 and Fig. S4A). Upon TRAP addition, endogenous Dab2
localized peripherally (Fig. 4A, Activated 3 min). Accordingly, the
localization of N-PTB was indistinguishable from endogenous
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PLoS ONE | www.plosone.org 3 November 2009 | Volume 4 | Issue 11 | e8007Figure 1. Dab2 N-PTB interacts with sulfatides. (A) Sequence alignment of Dab2 regions involved in sulfatide binding. Residues predicted to
interact with sulfatides and PtdIns(4,5)P2 are boxed. Consensus motifs are indicated at the bottom. hDab2, H. sapiens Dab2; mDab2, M. musculus
Dab2; rDab2, R. norvegicus Dab2; hDab1, H. sapiens Dab1; CeDab1, C. elegans Dab1; DmDab, D. melanogaster Dab. (B) Sphingolipid strips spotted with
the indicated lipids were probed with 0.2 mg/ml of Glutathione S-transferase (GST)-N-PTB. (C) Liposome binding assay for N-PTB and its mutants in
the presence (+) and absence (2) of sulfatides. S: supernatant; P: pellet. Bands were quantified using AlphaImager and normalized to the input (bars).
The figure shows data from a single experiment that was repeated three times with similar results. (D) Same as C but in the presence and absence of
PtdIns(4,5)P2. N-PTB, N-terminal Dab2 (amino acids 1-241); N-PTB
K25, N-PTB Lys25Ala; N-PTB
4M, N-PTB Lys25Ala, Lys49Ala, Lys51Ala and Lys53Ala;
N-PTB
K53K90, N-PTB Lys53Ala and Lys90Ala; N-PTB
K90, N-PTB Lys90Ala.
doi:10.1371/journal.pone.0008007.g001
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sulfatide-binding motifs (N-PTB
4M) reduced the localization of the
protein at the activated platelet surface by about 90% (Fig. 4C,
Activated 3 min), indicating a role for sulfatides in the localization
of N-PTB. Thus, we propose that the remaining N-PTB
4M
localized at the platelet surface (Fig. 4C, Activated 3 min) is most
likely bound to the integrin receptor through its RGD (Arg64,
Gly65, Asp66) motif, a sequence that specifically binds to integrin
receptors [35]. This model is supported by findings that show
Dab2 PTB binds to the aIIb domain of the integrin receptor
through the Dab2 RGD motif [9]. Indeed, mutation of Asp66 to
Glu (D66E) abolishes Dab2 interaction with the receptor [9]. Our
results show that N-PTB
D66E binds to a lesser extent to the
activated platelet surface (Fig. S4B and C). To confirm our model,
we investigated the direct binding of the Dab2 N-PTB constructs
with the endogenous integrin aIIbb3 receptor from activated
platelets by pull-down and immunoblotting. As expected, both
Dab2 N-PTB and N-PTB
4M bound to the receptor, whereas N-
PTB D66E did not (Text S1 and Fig. S4D). In addition, a
construct containing mutations in both sulfatide and the integrin
receptor binding sites (Dab2 N-PTB
5M; K25A/K49A/K51A/
K53A/D66E) was unable to associate with the integrin receptor,
mimicking the effect of the single D66E mutation in N-PTB (Fig.
S4D). Since this mutation does not abrogate binding to sulfatides,
but sulfatide-binding mutations in N-PTB
4M and N-PTB
5M do
(Fig. 1C and S4E), our data support a model in which Dab2 N-
PTB
D66E is preferentially available for sulfatide binding at the
platelet surface.
Interestingly, when platelets were fixed 10 min after activation,
endogenous Dab2, as well as N-PTB, N-PTB
4M,a n dN - P T B
D66E
exhibited complete internalization (Fig. 4A–C, E and Fig. S4B,
Activated 10 min). However, mutants showed less total internalized
p r o t e i nw h e nc o m p a r e dw i t ht h ew i l d - t y p ef o r m( F i g .4 B ,C ,a n dF i g .
S4B Activated 10 min; E, Internalization 10 min), as expected since
the amount of protein bound to the surface is also comparably reduced
(Fig. 4B, C, Activated 3 min; E, Binding 3 min). Since platelets are
known to internalize the integrin receptor [36], the accumulation of
intracellular protein over time is anticipated, especially for those
mutant proteins (i.e.,N - P T B
4M) that favor integrin binding (Fig. 4E).
Mutation in the PtdIns(4,5)P2-binding site, N-PTB
K53K90,d e c r e a s e d
the membrane localization of the protein by 58% (Fig. 4D, Activated
3 min; E, Binding 3 min), indicating that Lys53 is critical for both
sulfatide binding and localization of Dab2 at the platelet surface.
Furthermore, 10 min post-activation, the surface-bound N-PTB
K53K90
was internalized (Fig. 4D, Activated 10 min; E, Internalization
10 min). This result indicates that PtdIns(4,5)P2 binding is not required
for internalization of the extracellular N-PTB and that N-PTB
K53K90,
with reduced sulfatide-binding properties (Fig. 1C), is likely internalized
in an integrin receptor-dependent manner. PtdIns(4,5)P2,h o w e v e r ,
could interact with cytosolic Dab2 since this phosphoinositide mediates
Dab2 recruitment, local membrane destabilization, and deformation
during endocytosis [16].
N-PTB Is Internalized by an Actin Cytoskeleton-
Dependent Mechanism
To determine where Dab2 is delivered upon its internalization
later in platelet activation, we carried out immunofluorescence
Figure 2. Kinetic analysis of lipid binding by Dab2 N-PTB.
Interactions of N-PTB with immobilized sulfatide- (circles) and
PtdIns(4,5)P2-liposomes (squares) were analyzed by SPR. Resonance
units quantify the bound protein fraction at increasing protein
concentrations. Data represent the average of two independent
experiments.
doi:10.1371/journal.pone.0008007.g002
Figure 3. Sulfatides protect Dab2 N-PTB from thrombin
proteolysis. (A) N-PTB was incubated in the absence (left) and
presence (right) of thrombin and samples collected at the indicated
times were analyzed by SDS-PAGE. (B) N-PTB was pre-incubated with
control (top) and sulfatide liposomes (bottom) and incubated with
thrombin. Boundaries of the amino acid sequence of trypsin-digested
bands, obtained by mass spectrometry analysis, are indicated on the
right. The sequence GPLGS is translated from the vector. (C) Diagram of
the N-PTB region indicating sulfatide-binding (S) and thrombin
cleavage sites. (D) N-PTB was pre-incubated with control (top) and
PtdIns(4,5)P2 liposomes (bottom) and processed as described in A and
B. The figure shows data from a single experiment that was repeated
two times with similar results.
doi:10.1371/journal.pone.0008007.g003
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PLoS ONE | www.plosone.org 5 November 2009 | Volume 4 | Issue 11 | e8007Figure 4. Role of sulfatides and PtdIns(4,5)P2 in Dab2 N-PTB localization. (A) Endogenous Dab2 (red) from washed platelets was monitored
prior to activation (Unactivated), and 3 and 10 min after TRAP addition. N-PTB (B), N-PTB
4M (C), or N-PTB
K53K90 (D) (all in red) were monitored at the
same times. Phalloidin (green) stains actin stress fibers. (E) Quantification of binding (3 min) and internalization (10 min) of N-PTB, N-PTB
4M, and
N-PTB
K53K90 are represented by bars. The average mean pixel intensity of approximately 450 platelets was quantified for each analysis. The average
mean pixel intensity of the endogenous protein in a given experiment was then subtracted from the average mean pixel intensity of a sample
containing exogenous protein to yield only the net mean pixel intensity generated by the exogenous proteins. The net mean pixel intensity values of
the N-PTB mutant proteins were compared to the net mean pixel intensity of the wild type N-PTB (referred as 100%) at 3 min. The percentage of the
protein that was internalized (10 minutes) for each construct was determined by multiplying the percentage of protein internalized at 10 minutes
(compared to the wild type N-PTB at 10 minutes) by the amount of protein bound for each construct at 3 minutes. (F–H) Washed platelets were
treated with chlorpromazine, further incubated with N-PTB (F), N-PTB
4M (G), or N-PTB
D66E (H) and processed as above. (I) Quantification of internalized
(10 min) N-PTB, N-PTB
4M, and N-PTB
D66E in the presence of chlorpromazine compared to their vehicle. Quantifications were performed as described
in (E). (J–K) Washed platelets treated with vehicle (J) or cytochalasin D (K) and further incubated with N-PTB were processed as in A. In panels B–D, F–
H and J–K, each experiment was normalized to that shown in A. The figure shows data from a single experiment that was repeated two times with
similar results. N-PTB
D66E, N-PTB Asp66Glu. Bar, 5 mm.
doi:10.1371/journal.pone.0008007.g004
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of a-granules (Text S1 and Fig. S5). Interestingly, we found that
Dab2 co-localizes with PF4 before and after degranulation,
suggesting that the internalized protein is recycled and again
stored in a-granules. This is in agreement with the proposed
mechanism of constitutive trafficking of internalized proteins to a-
granules throughout the lifespan of the platelet [2]. To further
investigate the mechanism by which N-PTB is internalized in
platelets, we employed inhibitors of actin polymerization and
endocytosis. Platelets exhibited peripheral N-PTB shortly after
their activation in the presence of all inhibitors tested (Fig. 4F–H,
J, K Activated 3 min and Fig. S6). No inhibition of N-PTB
internalization was observed when activated platelets were
incubated with either methyl-b-cyclodextrin (MBCD), a choles-
terol-depleting agent for caveolae-mediated endocytosis [37], or
filipin, an inhibitor of caveolae formation [38] (Fig. S6A and B,
Activated 10 min). Intriguingly, chlorpromazine, an inhibitor of
clathrin-mediated endocytosis [39], weakly inhibited N-PTB
internalization (Fig. 4F, I). When chlorpromazine was tested in
the presence of N-PTB
4M, internalization of the protein was
reduced by more than 50%, whereas N-PTB
D66E was unaffected
(Fig. 4G and H, Activated 10 min; I, Fig. S6C–E). Since integrin
receptors are internalized by clathrin-mediated endocytosis [40],
we propose that chlorpromazine preferentially inhibits the
internalization of the integrin receptor-bound pool of N-PTB.
Finally, internalization of N-PTB was completely inhibited in the
presence of cytochalasin D, an actin polymerization inhibitor [41]
(Fig. 4J and K, Activated 10 min). Overall, our results support a
mechanism of sulfatide-mediated Dab2 internalization that is lipid
raft and clathrin-independent but actin cytoskeleton-dependent.
Sulfatides Modulate the Availability of Dab2 for the
Integrin Receptor
Binding of fibrinogen to platelets mediates aggregation during
blood clotting [42], an event regulated by Dab2 PTB, which
competes with fibrinogen for integrin binding at the platelet
surface [9]. To understand whether sulfatide binding by N-PTB
governs integrin receptor function in platelets, we performed an
adhesion assay. As expected, N-PTB
D66E did not affect platelet
adhesion to fibrinogen, whereas RGDS, a low-affinity fibrinogen
receptor antagonist [43], and N-PTB reduced platelet adhesion by
about 7 and 13.5%, respectively (Fig. 5A). In agreement with our
model, N-PTB
4M inhibited cell adhesion more efficiently (18.5%)
(Fig. 5A), suggesting that abolishing sulfatide binding makes a
larger pool of N-PTB available to compete with fibrinogen for
binding to the integrin receptor. In support of this hypothesis, N-
PTB reduced PAC-1 antibody binding to the integrin receptor by
36%, whereas N-PTB
4M decreased it by about 45% when
analyzed by flow cytometry (Fig. 5B). We further investigated
the role of sulfatides in the integrin receptor and Dab2 functions in
activated platelets (Fig. 5C). Activated platelets increased the levels
of the integrin receptor at their surface in the presence of sulfatide-
enriched liposomes, consistent with the hypothesis that sulfatides
activate the integrin receptor via signaling through P-selectin [44].
In the presence of Dab2 N-PTB, however, the expression levels of
the integrin receptor mirrored the levels observed in the absence of
exogenous sulfatides (Fig. 5C), indicating that N-PTB, but not N-
PTB
4M, sequestered sulfatide-liposomes from the platelet surface.
Proposed Model for Lipid-Mediated Dab2 Action
Based on our results, we propose the existence of two pools of
Dab2 at the surface of activated platelets (Fig. 5D). One pool
negatively regulates platelet aggregation by competing with
fibrinogen for binding to the aIIbb3 integrin receptor, whereas a
Figure 5. Two pools of Dab2 exist at the activated platelet
surface. (A) Washed platelets were activated in fibrinogen-coated wells
in the presence of N-PTB
D66E, RGDS peptide, N-PTB, or N-PTB
4M.
Inhibition of platelet adhesion was quantified compared to N-PTB
D66E.
Data represent the results of two independent experiments. *, P,0.03;
**, P,0.01. (B) Washed platelets were incubated with PAC-1 antibody in
the presence of control peptide (PPPVKKRAAKCLLL), RGDS, N-PTB, or
N-PTB
4M and binding to the integrin receptor monitored by flow
cytometry. Data represent the results of three independent experi-
ments. *, P,0.03; **, P,0.002. (C) The Dab2 N-PTB sequesters sulfatides
needed for integrin receptor expression at the activated platelet
surface. Activated platelets (No lip) were incubated with liposomes
without (C-lip) or with sulfatides (S-lip), and in the absence or presence
of either N-PTB (N-PTB+S-lip) or N-PTB
4M (N-PTB
4M+S-lip). Expression of
the integrin receptor was quantified using a PAC-1 antibody. Data
represent the results of two independent experiments. (D) Proposed
model for the role of sulfatides in partitioning Dab2 during platelet
activation. Upon platelet activation and degranulation, Dab2 is released
extracellularly and is partitioned between the integrin receptor (to
inhibit platelet aggregation) and the membrane surface by interaction
with sulfatides (red balls). Dab2 surface binding is transient since the
protein is internalized shortly by an actin-dependent mechanism and
accumulated intracellularly in a-granules. Binding of cytoplasmic Dab2
to PtdIns(4,5)P2 (blue balls) may contribute to anchoring the protein to
the cytosolic side of the platelet membrane.
doi:10.1371/journal.pone.0008007.g005
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nonsulfatide-bound pool of Dab2 and, thus, controls the extent of
clotting. Instead, the sulfatide-bound pool remains protected from
thrombin cleavage and modulates the clotting response by
sequestering Dab2 away from binding to the aIIbb3 integrin
receptor. Interestingly, whereas the integrin receptor pool appears
to be specifically internalized by clathrin-mediated endocytosis,
internalization of both Dab2 pools depends upon the dynamic
nature of the actin cytoskeleton.
Sulfatides are present at the surface of blood cells including
myeloid cells, erythrocytes, and platelets [45,46,47]. Hence, our
findings might extend to other mediators of blood clotting. For
example, the haemostatic glycoprotein vWF also binds both
sulfatides and the aIIbb3 integrin receptor, through its RGD
motif, at the platelet surface [48]. Moreover, activated platelets
express P-selectin, a transmembrane protein known to bind
sulfatides and necessary to stabilize platelet and heterotypic
aggregates [22,44]. The major questions to be addressed are what
mechanism dominates and under what circumstances, and how
can these mechanisms be triggered in the context of our model.
Upon platelet activation, integrin receptors mediate clustering of
PtdIns(4,5)P2 at the inner leaflet of the plasma membrane [49].
Activated platelets recycle integrin receptor, thus, downregulating
the adhesiveness of platelets later in aggregation [36]. Since cytosolic
Dab2 has been shown to bind to the b3 subunit of the integrin
receptor [50], we speculate that PtdIns(4,5)P2 docks cytoplasmic
Dab2 at the platelet membrane facilitating its endocytic function.
Cytosolic Dab1 is expressed exclusively in the brain where it
participates in the Reelin signaling pathway and is required for the
regulation of neuronal migration and positioning during embry-
onic development [51]. Sulfatides are the major constituent of the
myelin sheath in the central and peripheral nervous system and
they are found at the extracellular leaflet of the membrane of
oligodendrocytes and Schwann cells [52]. In astrocytes and
neurons, however, sulfatides are located intracellularly in large
vesicles [53,54]. Since human Dab1 exhibits canonical sulfatide-
binding motifs at the N-terminus (Fig. 1A), it will be of interest to
study whether the function of this protein is regulated by
intracellular sulfatides in neuronal cells.
In conclusion, our work is the first demonstration that the
protein Dab2, a platelet aggregation inhibitor, specifically binds to
sulfatides and that this interaction modulates the progression of
platelet activation. These findings further contribute to our
understanding of how the dynamics of the ligand-dependent
partitioning of Dab2 modulates platelet aggregation, thus,
promoting the development of novel antiplatelet strategies.
Supporting Information
Text S1 Supplementary text file.
Found at: doi:10.1371/journal.pone.0008007.s001 (0.05 MB
DOC)
Table S1 Prediction of secondary structure composition of Dab2
N-PTB and its mutants. All secondary structural elements content
are in %. R and D represent predicted regular and distorted
secondary structure elements, respectively. NRMSD is the
normalized root mean square difference of the experimental and
calculated spectra. Predictions were generated using DICHRO-
WEB and deconvoluted using CDSSTR.
Found at: doi:10.1371/journal.pone.0008007.s002 (0.53 MB TIF)
Figure S1 Identification of the residues of Dab2 N-PTB involved
in sulfatide binding. (A) Membranes spotted with the indicated
amount of sulfatides were probed with 1 mg/ml GST or GST-Dab2
N-PTB constructs. (B) Dose-dependent binding of the Dab2 N-PTB
and Dab2 PTB4M was tested using sulfatide-enriched liposomes.
(C) Liposome binding assay of the indicated Dab2 N-PTB mutants
were assayed in the presence (+) and absence (2) of sulfatides. ‘S’
and ‘P’ represent proteins present in supernatant and pellet
fractions, respectively. Bands were quantified using AlphaImager
and normalized to the input amount. The figure shows data from a
single experiment that was repeated three times with similar results.
N-PTBK49, N-PTB Lys49Ala; N-PTBK53, N-PTB Lys53Ala; N-
PTBK25K49, N-PTB Lys25Ala and Lys49Ala.
Found at: doi:10.1371/journal.pone.0008007.s003 (1.73 MB TIF)
Figure S2 Mutations in Dab2 N-PTB do not alter the overall
secondary structure of the protein. Far-UV circular dichroism
spectra of Dab2 N-PTB and its mutants (5 mM each) were
converted to mean residue ellipticity using DICHROWEB and
deconvoluted using CDSSTR.
Found at: doi:10.1371/journal.pone.0008007.s004 (0.73 MB TIF)
Figure S3 Sulfatide-binding amino acids Lys25 and Lys49 are
dispensable for PtdIns(4,5)P2 binding. Mutants N-PTBK49, N-
PTBK53 and N-PTBK25K49 were analyzed for PtdIns(4,5)P2
binding by liposome-binding assay in the presence (+) and absence
(2) of PtdIns(4,5)P2. ‘S’ and ‘P’ represent proteins present in
supernatant and pellet fractions, respectively. Bands were
quantified using AlphaImager and normalized to the input
amount. The figure shows data from a single experiment that
was repeated three times with similar results.
Found at: doi:10.1371/journal.pone.0008007.s005 (0.84 MB TIF)
Figure S4 Mutation of Asp66 to Glu in Dab2 N-PTB reduces
binding of the protein to the platelet surface but it does not affect
sulfatide binding. (A) Washed human platelets were incubated with
bovine serum albumin (BSA; 1.9 mM) for 5 min at room tempera-
ture. Samples were fixed prior to activation (Unactivated), 3 min
(Activated 3 min), and 10 min (Activated 10 min), after the addition
of 10 mM TRAP and localization was monitored by immunofluo-
rescence. (B) Mutation of the RGD motif reduces Dab2 N-PTB
(Dab2 N-PTBD66E) localization at the platelet surface. Washed
human platelets were incubated with Dab2 N-PTBD66E and
processed as described in A. (C) Quantification of binding (3 min)
and internalization (10 min) of Dab2 N-PTB and N-PTBD66E are
represented by diagram bars. Approximately 450 platelets were
quantified for each analysis as described in Methods. The percentage
of the protein that was internalized (10 min) for each construct was
determined by multiplying the percentage of protein internalized at
10 min (compared to the wild type N-PTB at 10 min) by the amount
of protein bound for each construct at 3 min. Scale bar: 5 mm. (D)
Binding of Dab2 N-PTB constructs with the endogenous aIIbb3
integrin receptor of activated platelets. The indicated constructs (as
GST fusion proteins-bound beads) were incubated with activated
platelets for 1 h at room temperature. After lysis, beads were washed,
samples subjected by SDS-PAGE and analyzed by western blotting.
Bands were quantified using using AlphaImager and normalized to
the input amount. The figure shows data from a single experiment
that was repeated two times with similar results.(E) Liposome binding
assay of N-PTB, N-PTB4M, N-PTBD66E and N-PTB5M was
carried out in the presence (+) and absence (2) of sulfatides. ‘S’ and
‘P’ represent proteins present in supernatant and pellet fractions,
respectively. Bands were quantified using AlphaImager and normal-
ized to the input amount. The figure shows data from a single
experiment that was repeated two times with similar results.
Found at: doi:10.1371/journal.pone.0008007.s006 (3.46 MB TIF)
Figure S5 Internalized Dab2 co-localizes with PF4 in activated
platelets. Dab2 (red) intracellular localization in unactivated (A)
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marker of a-granules (green). The merge reveals the co-
localization of Dab2 with the a-granule compartments.
Found at: doi:10.1371/journal.pone.0008007.s007 (0.16 MB TIF)
Figure S6 Analysis of platelet localization of the Dab2 N-PTB
constructs using inhibitors of endocytosis. (A–B) Washed human
platelets were pre-incubated with MBCD (A) or filipin (B) and further
incubated with Dab2 N-PTB (1.9 mM) for 5 min at room temperature.
Samples were fixed prior to activation (Unactivated), 3 min (Activated
3 min), and 10 min (Activated 10 min), after the addition of 10 mM
TRAP and localization was monitored by immunofluorescence. (C–E)
Vehicle controls for the chlorpromazine experiment shown in
Figure 4F–H. Scale bar: 5 mm. The figure shows data from a single
experiment that was repeated two times with similar results.
Found at: doi:10.1371/journal.pone.0008007.s008 (1.18 MB TIF)
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